share_log

Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals

Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals

坎托·菲茨杰拉德重申增持ORIC制药
Benzinga ·  05/28 09:13

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

康泰福克兰分析师Prakhar Agrawal重申oric Pharmaceuticals(纳斯达克: oric pharmaceuticals)为超额配重。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发